Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Total Debt (2016 - 2026)

Ironwood Pharmaceuticals' Total Debt history spans 12 years, with the latest figure at $584.7 million for Q4 2025.

  • On a quarterly basis, Total Debt rose 51.86% to $584.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $584.7 million, a 51.86% increase, with the full-year FY2025 number at $584.7 million, up 51.86% from a year prior.
  • Total Debt hit $584.7 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $584.5 million in the prior quarter.
  • Over the last five years, Total Debt for IRWD hit a ceiling of $599.1 million in Q2 2023 and a floor of $112.9 million in Q2 2021.
  • Historically, Total Debt has averaged $394.1 million across 5 years, with a median of $425.0 million in 2024.
  • Biggest five-year swings in Total Debt: decreased 29.06% in 2024 and later soared 51.86% in 2025.
  • Tracing IRWD's Total Debt over 5 years: stood at $116.9 million in 2021, then increased by 3.19% to $120.6 million in 2022, then surged by 314.29% to $499.6 million in 2023, then dropped by 22.93% to $385.0 million in 2024, then skyrocketed by 51.86% to $584.7 million in 2025.
  • Business Quant data shows Total Debt for IRWD at $584.7 million in Q4 2025, $584.5 million in Q3 2025, and $584.3 million in Q2 2025.